KalVista Pharmaceuticals (KALV) Times Interest Earned (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Times Interest Earned of -$16.75 in Q3 2025, up 77.41% quarter-over-quarter from -$74.18 in Q1 2016.
KalVista Pharmaceuticals' Times Interest Earned history runs 4 years deep, the most recent figure standing at -$16.75 for Q3 2025.
- In Q3 2025, Times Interest Earned changed N/A year-over-year to -$16.75; the TTM figure through Jul 2025 stood at -$57.94 (changed N/A YoY), while the FY2025 annual figure was -$32.5, changed N/A from the prior year.
- Times Interest Earned came in at -$16.75 for Q3 2025 at KalVista Pharmaceuticals, up from -$74.18 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$16.75 in Q3 2025 to a low of -$16.75 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -16.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -16.75 |
| Mar 31, 2016 | -74.18 |
| Dec 31, 2015 | -63.28 |
| Sep 30, 2015 | -51.57 |
| Jun 30, 2015 | -33.53 |
| Mar 31, 2015 | -5.86 |
| Sep 30, 2014 | -9.99 |
| Jun 30, 2014 | -29.35 |
| Mar 31, 2014 | -23.20 |